key: cord-0959374-v7vc034e
authors: Burgos‐Blasco, Barbara; Güemes‐Villahoz, Noemi; Vidal‐Villegas, Beatriz; Donate‐Lopez, Juan; Garcia‐Feijoo, Julian
title: Evaluation of retinotoxicity of COVID‐19 treatment: hydroxychloroquine and lopinavir/ritonavir
date: 2020-08-12
journal: J Med Virol
DOI: 10.1002/jmv.26420
sha: 0bffdcc1eb24fd988b8d725e8aedd56e4c9ea169
doc_id: 959374
cord_uid: v7vc034e

Despite no established treatment for COVID‐19, hydroxychloroquine (HCQ) and lopinavir/ritonavir are being used. We read with interest the recent article of Chong et al.(1) This article is protected by copyright. All rights reserved.

None of the patients reported visual loss during infection, nor after resolution. Funduscopic examination did not show visible macular alterations. In OCT, no thinning of the outer retinal layers or disruption of the ellipsoid zone was noted (Fig. 1B) . In FAF, no abnormal areas of hyper or hypofluorescence were observed.

HCQ and lopinavir/ritonavir are being used in COVID-19 and could produce retinotoxicity. In a large series of patients, most of them treated with both drugs, we found no macular alterations in OCT and FAF.

HCQ retinotoxicity is asymptomatic, dose-dependent and increases in patients suffering from renal disease, with maculopathy or who use tamoxifen. Characteristic alterations in HCQ toxicity include thinning of the photoreceptor layers, disruption of the interdigitation zone and outer nuclear layer thinning. FAF can reveal early damage as an area of increased autofluorescence. 2 None of our patients presented these findings.

Regarding ritonavir, macular alterations described in the literature include macular retinal pigment epitheliopathy (granular appearance), intraretinal crystalline deposits and parafoveal telangiectasia. Patients with abnormal liver function are at a higher risk of retinotoxicity, the former being only present in 2 of our patients. Toxicity appears after chronic use and is usually associated to a decrease in visual acuity, which none of our patients referred. 3, 5 Although most patients were on both drugs, the doses used in COVID-19 are shorter in time than those used in other diseases, normally chronic.

This supports the idea that there are is a low expected-risk of retinal effects in the future, although long-term follow up is needed for confirmation.

The study has several limitations. Firstly, it is carried out on a relatively low sample considering the low incidence of retinotoxicity described. In addition, the changes were evaluated qualitatively and there were no previous examinations of the patients to compare.

Nevertheless, this is the first study to analyze the changes in OCT and FAF with COVID-19 treatment. These are short-term results, although we have not observed any qualitative alterations characteristic of these drugs.

Despite it being a long latency period toxicity, it seems unlikely that with the This article is protected by copyright. All rights reserved.

doses used, future changes will occur. Currently, the World Health Organization does not recommend the use of HCQ in combination with antivirals. 6 Undoubtedly, further research and longer follow-up is needed to determine long-term consequences of these drugs. 

Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID

This article is protected by copyright. All rights reserved.